Prime Medicine wins arbitration vs Beam Therapeutics, plans FDA IND filing for genetic liver disease treatment. $PRME stock rises 12%.
Prime Medicine is headed for the clinic after winning a dispute with Beam Therapeutics, another gene editing biotech with roots in the same lab.
Arbitrators …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Prime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed…
Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on…
AstraZeneca, Ionis report major trial failure, White House pushes for American drug manufacturing, and more biotech news from The…
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
As Amgen strives to become the industry’s top player in cardiometabolic risk reduction by the start of the next decade, the…
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…
